Short Interest Worth Mentioning Today: A Reversal for Collegium Pharmaceutical Incorporated (NASDAQ:COLL) Is Not Near. The Stock Has Rise in Shorts

November 30, 2016 - By Marguerite Chambers   ·   0 Comments

Short Interest Worth Mentioning Today: A Reversal for Collegium Pharmaceutical Incorporated (NASDAQ:COLL) Is Not Near. The Stock Has Rise in Shorts

The stock of Collegium Pharmaceutical Incorporated (NASDAQ:COLL) registered an increase of 10.58% in short interest. COLL’s total short interest was 2.81M shares in November as published by FINRA. Its up 10.58% from 2.54M shares, reported previously. With 462,400 shares average volume, it will take short sellers 6 days to cover their COLL’s short positions. The short interest to Collegium Pharmaceutical Incorporated’s float is 25.93%. The stock decreased 0.31% or $0.05 during the last trading session, hitting $16.31. Collegium Pharmaceutical Inc (NASDAQ:COLL) has declined 9.84% since April 27, 2016 and is downtrending. It has underperformed by 15.07% the S&P500.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The company has a market cap of $444.88 million. The Firm focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. It currently has negative earnings. The Company’s lead product candidate, Xtampza ER , is an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication.

Collegium Pharmaceutical Inc (NASDAQ:COLL) Ratings Coverage

Out of 2 analysts covering Collegium Pharmaceutical Inc (NASDAQ:COLL), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Collegium Pharmaceutical Inc has been the topic of 2 analyst reports since February 19, 2016 according to StockzIntelligence Inc. The stock of Collegium Pharmaceutical Inc (NASDAQ:COLL) earned “Outperform” rating by William Blair on Friday, February 19. The rating was initiated by Gabelli with “Buy” on Tuesday, September 13.

COLL Company Profile

Collegium Pharmaceutical, Inc., incorporated on July 01, 2014, is a specialty pharmaceutical company. The Firm focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza), is an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication.

Another recent and important Collegium Pharmaceutical Inc (NASDAQ:COLL) news was published by Marketwatch.com which published an article titled: “/quotes/zigman/3870025/realtime” on April 19, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>